Do You Need a License to Improve a Patented Medical Device, Drug, or Diagnostic?

You need a license to improve a patented medical device, drug, or diagnostic if your improved product, or the work you do to develop it, still falls within a valid, unexpired claim and you can't design around that claim or rely on a defense. Inventing the improvement takes no one's permission, and the Patent Act treats improvements as patentable subject matter. Using it is a different matter, because a patent doesn't give its owner the right to practice anything. Under 35 U.S.C. § 154(a)(1), it gives the owner the right to exclude others from making, using, offering for sale, selling, or importing the claimed invention. Anyone who does those things with a patented invention without authority infringes under 35 U.S.C. § 271(a).

Improvement Patents and Blocking Patents

Section 101 of the Patent Act expressly covers "any new and useful improvement" of a machine, manufacture, composition, or process. A patent on your improvement gives you the right to exclude others from the improvement and no right to practice the underlying invention. If the original patent claims a catheter with elements A, B, and C and you add element D, your catheter still has A, B, and C, and it still infringes a typical "comprising" claim.

The result is a pair of blocking patents. The original patentee can't use your improvement without your permission, and you can't sell your improved product without theirs. That standoff is often where licensing leverage comes from: a well-claimed improvement patent can turn a request for permission into a negotiated cross-license, particularly when your improvement is the version the market actually wants.

Experimental Use and the FDA Safe Harbor

The United States has no general "research exemption" for commercial development, and the common-law experimental use defense is extremely narrow. In Madey v. Duke University, 307 F.3d 1351 (Fed. Cir. 2002), the Federal Circuit limited it to acts done for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry. The court held that it does not cover research that furthers an institution's legitimate business, even at a nonprofit university.

For life-sciences companies, the more useful provision is 35 U.S.C. § 271(e)(1), which exempts uses of a patented invention "solely for uses reasonably related to the development and submission of information" under a federal law regulating drugs. The Supreme Court applied that provision to medical devices in Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990). It later held in Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005) that the provision covers preclinical studies at least as long as there is a reasonable basis to believe the compound tested could be the subject of an FDA submission and the experiments will produce the types of information relevant to an IND or NDA, even if that compound never becomes one.

Commercial manufacture, stockpiling, sales, and marketing fall outside the safe harbor. Activities that generate information for purposes other than regulatory submission stand on less certain ground, and so does the use of patented research tools that are not themselves subject to FDA approval. We tell clients that work done in anticipation of FDA approval or clearance should be directly tied to that purpose. If you are making or using something validly claimed in a competitor's patent for commercial purposes, you may be infringing, and we advise avoiding those activities altogether.

Improving a Patented Drug, Biologic, Medical Device, or Diagnostic

An improved formulation, dosage form, or new indication of an approved drug often goes through a 505(b)(2) application that relies on the reference drug. That route brings in the Hatch-Waxman patent-certification framework, including Orange Book listings and the artificial act of infringement under 35 U.S.C. § 271(e)(2). A drug "improvement" program is usually a patent-litigation planning exercise as much as a regulatory one.

Biologics raise different patent questions depending on whether the improved product is a new biologic filed under its own application or a product that relies on a reference product. Manufacturing-process and cell-line patents often matter as much as patents on the molecule.

Medical devices have no Orange Book, so no public list tells you which patents matter. If your improved device relies on a predicate in a 510(k), you are effectively telling the market which product yours resembles, which makes the predicate's patent portfolio worth reviewing before you file.

Many diagnostic method claims are vulnerable on patent eligibility grounds after Mayo and Myriad, while claims to kits, reagents, and instruments often survive more easily. Software claims face their own eligibility test under Alice. The medical-practitioner exemption in 35 U.S.C. § 287(c) removes infringement remedies against physicians and related health-care entities for certain procedures. Because it expressly excludes the use of patented machines and compositions and the practice of biotechnology patents, it rarely protects a product company.

Modifying a Patented Product You Bought

When a patentee sells a product, its patent rights in that item are exhausted, regardless of any post-sale restrictions it tries to impose (Impression Products, Inc. v. Lexmark International, Inc. (2017)). Purchasers can generally use, repair, and resell what they bought. Exhaustion does not let you make a new patented article, and modification that amounts to reconstruction is outside it. Contract restrictions that no longer support a patent claim may still support a breach-of-contract claim. On the regulatory side, modifying or remanufacturing a cleared device can trigger FDA obligations of its own.

Improvement Clauses in License and Research Agreements

If you are already a licensee, collaborator, or recipient of materials, read your agreements before you assume the improvement is yours. License agreements often include grant-back clauses. Material transfer agreements, sponsored research agreements, clinical trial agreements, and supply agreements frequently assign, license, or restrict improvements, sometimes broadly enough to reach work you consider independent.

This comes up often for clients affiliated with a university or private research institute, especially when federal grant funding supported development of the technology. Under the Bayh-Dole Act, those institutions typically elect to retain title to federally funded inventions and take on obligations to commercialize them, so they require written assignment from their researchers and prosecute the related patent applications themselves. Read those terms carefully. Outside academia, employment agreements deserve the same scrutiny. Conception and reduction to practice outside the employment typically belong to the inventor, but using employer resources can change that.

Research Exemptions Outside the United States

Other systems are sometimes more permissive for research. Article 27 of the Agreement on a Unified Patent Court excludes from patent rights acts done for experimental purposes relating to the subject matter of the patented invention, along with regulatory-testing acts for medicinal products allowed under the EU's human and veterinary medicines directives. That regulatory-testing exception does not extend to medical device testing. National laws vary, and a development program that is safe in one jurisdiction may not be in another.

Assessing Whether You Need a License

We start with the claims. That means confirming which patents remain in force, including term extensions under 35 U.S.C. § 156, and mapping the improved product against each independent claim. Validity gets assessed where it matters. We also decide which development activities fall within the safe harbor and whether an improvement patent should be filed early enough to create negotiating leverage. The outcome is often a mix: a design-around for some patents, a challenge to others, and a cross-license for the one that actually blocks you.

Many of our clients have taken two paths to market, and one of them may avoid a competitor's claims. The first is the FDA-regulated route, where clients rely on the safe harbor during the approval or clearance process. Some have received cease-and-desist letters after the first commercial sale, and cross-license negotiations have resolved some of those disputes. When litigation is imminent, we bring in co-counsel for the federal litigation, counterclaims, PTAB invalidity challenges and the rest. The second route is direct to consumer, where that's available, and the product is typically different enough from the FDA-regulated device to avoid the competitor's claims. When those claims are broad, clients typically engineer around them.

Careful written communication with opposing counsel matters more than anything else in these disputes. The judgment and word choices in those letters are typically where a dispute begins to resolve before anyone files suit.

If you're planning an improvement on a patented product and want a claim-by-claim read before you commit, contact us.

This FAQ provides general information, not legal advice, and does not create an attorney-client relationship. Outcomes depend on specific facts and jurisdictions. See our Legal Notices.